Stocks · News reference
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $35 to $36.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On Thursday, Denali Therapeutics (NASDAQ:DNLI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call
B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.
UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $34.
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 5.56 percent increase over losses of $(0.72) per share